Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Ribomic Inc.

Market Cap 4.78B 29.83M 25.73M 23.66M 22.27M 41.84M 2.81B 42.19M 280M 109M 1.38B 112M 110M P/E 2024
-3.24x
P/E 2025 -3.89x
Enterprise Value 1.74B 10.87M 9.38M 8.62M 8.12M 15.25M 1.03B 15.38M 102M 39.79M 504M 40.81M 39.94M EV / Sales 2024
-
EV / Sales 2025 666x
Free-Float
96.31%
Yield 2024 *
-
Yield 2025 -
03-19 Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan MT
03-19 Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment CI
03-10 Ribomic Reports Positive Phase II Results For Achondroplasia Drug MT
03-10 Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia CI
02-12 Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
01-14 Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006 MT
01-14 RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy CI
11-21 Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial MT
07/10/25 Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol MT
07/10/25 Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and Older CI
07/10/25 Ribomic announces positive phase 2 cohort 2 results for umedaptanib pegol in achondroplasia RE
25/09/25 Ribibo, Inc. Announces Discovery of Therapeutic Effects of Umedaptanib Pegol in A Diabetic Retinopathy Model and New Patent Application for Use CI
20/08/25 Ribomic Reports Sustained Efficacy of Achondroplasia Drug in Long-Term Trial MT
1 day+5.08%
Current month-11.43%
1 month-17.33%
3 months-37.37%
6 months-19.48%
Current year-20.51%
1 week 57
Extreme 57
64
1 month 57
Extreme 57
80
Current year 57
Extreme 57
120
1 year 57
Extreme 57
141
3 years 57
Extreme 57
170
5 years 57
Extreme 57
944
10 years 57
Extreme 57
1,109
Manager TitleAgeSince
President 78 31/03/2012
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer 38 30/09/2023
Director TitleAgeSince
Director/Board Member 77 31/05/2016
Director/Board Member 78 30/09/2005
Director/Board Member 68 31/05/2021
Change 5-day change 1-year change 3-year change Capi.($)
+5.08%0.00%-31.87%-61.25% 20.24M
+3.23%+2.93%+61.50%+113.87% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.04%+6.61%-13.27%-18.06% 22.63B
+3.07%-0.60%-3.09%+392.25% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.71%+11.09%-38.81% 14.83B
+0.65%-1.04%+25.60%+174.70% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.27%+4.82%+75.35%+104.79% 11.56B
Average +1.44%-0.32%+19.46%+74.13% 20.97B
Weighted average by Cap. +1.53%+0.18%+31.62%+90.67%

Financials

2024 2025
Net sales - 2M 12.48K 10.77K 9.9K 9.32K 17.51K 1.18M 17.66K 117K 45.68K 578K 46.85K 45.85K
Net income -1.02B -6.39M -5.51M -5.07M -4.77M -8.97M -603M -9.04M -60.07M -23.39M -296M -23.99M -23.47M -1.02B -6.35M -5.48M -5.04M -4.74M -8.91M -600M -8.99M -59.72M -23.25M -294M -23.85M -23.34M
Net Debt -3.4B -21.21M -18.3M -16.83M -15.84M -29.76M -2B -30.01M -199M -77.63M -983M -79.62M -77.92M -3.04B -18.95M -16.35M -15.03M -14.15M -26.59M -1.79B -26.81M -178M -69.36M -878M -71.14M -69.62M
Logo Ribomic Inc.
RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
Employees
-
Date Price Change Volume
17/06/26 62.00 ¥ +5.08% 1,080,600
16/06/26 59.00 ¥ -4.84% 879,700
15/06/26 62.00 ¥ -1.59% 155,300
12/06/26 63.00 ¥ +1.61% 546,600
11/06/26 62.00 ¥ 0.00% 303,100

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4591 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!